Company profile: Arthex Biotech
1.1 - Company Overview
Company description
- Provider of antisense RNA and anti-miR therapies for Myotonic Dystrophy, including a program targeting upregulated miRNA to address the disease’s root cause and improve delivery to muscle tissue, and early preclinical development of an innovative Type 1 Myotonic Dystrophy drug with in vitro toxicity and preliminary pharmacokinetic and pharmacodynamic studies.
Products and services
- Antisense RNA Treatment Development: microRNA-targeted antisense RNA programs architected against genetic diseases, leveraging drug discovery expertise in neuromuscular indications to produce candidate therapeutics for Myotonic Dystrophy patients
- Anti-miR for Myotonic Dystrophy: custom-engineered antagomiR oligonucleotide therapy targeting upregulated miRNA to address disease root cause, with improved delivery approaches to muscle tissue in Myotonic Dystrophy patients
- Early Preclinical Phases for Type 1 Myotonic Dystrophy Drug: in vitro package conducting toxicity assays and preliminary pharmacokinetic and pharmacodynamic evaluations to characterize candidate activity for Myotonic Dystrophy treatment
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Arthex Biotech
NLS Pharmaceutics
HQ: Switzerland
Website
- Description: Provider of clinical-stage drug development focused on neurobehavioral and neurocognitive disorders and their pharmacognosia, using a patient-centered, target-specific approach via collaborations with industry and academia. Products include Quilience, an extended-release mazindol for excessive daytime sleepiness and cataplexy in narcolepsy, and Nolazol, a controlled-release mazindol for ADHD.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NLS Pharmaceutics company profile →
Anelixis Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage drug development focused on immune modulatory therapies for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD); facilitates pre-clinical drug development. Based in Cambridge, Massachusetts.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Anelixis Therapeutics company profile →
Marinus Pharmaceuticals
HQ: United States
Website
- Description: Provider of drugs and clinical research for seizure disorders. Offerings include ganaxolone, a GABAA receptor modulator for status epilepticus and rare epilepsies. The company reformulates, develops, and commercializes therapies and conducts clinical trials, and also targets neurological, psychiatric, and pain disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Marinus Pharmaceuticals company profile →
Emalex Biosciences
HQ: United States
Website
- Description: Provider of biotech therapies for central nervous system disorders, developing Ecopipam, a novel investigational D1 receptor dopamine blocker targeting Tourette syndrome, and conducting an FDA-regulated Phase 3 trial (EBS-101) in children, adolescents, and adults with Tourette’s. Also pursuing investigational treatments for childhood-onset fluency disorder (stuttering) in adults.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Emalex Biosciences company profile →
Synchron
HQ: United States
Website
- Description: Provider of neuromodulation solutions in bioelectronics medicine for previously-untreatable nervous system conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synchron company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Arthex Biotech
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Arthex Biotech
2.2 - Growth funds investing in similar companies to Arthex Biotech
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Arthex Biotech
4.2 - Public trading comparable groups for Arthex Biotech
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →